Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes.

Molecular modelling of the anti-ulcerative agent, omeprazole, with the putative active sites of cytochromes P4503A4 and P4502C19, enzymes which are the major catalysts of omeprazole metabolism in man, are reported. Interactive docking of omeprazole in both CYP3A4 and CYP2C19 gives rise to binding orientations which are consistent with both the known sites of metabolism reported for these isoforms and with evidence from site-directed mutagenesis experiments on CYP2C19, a P450 associated with genetic polymorphism in human drug metabolism. The potential P450 enzymic interactions, inhibition and induction of omeprazole are discussed in the light of molecular modelling and QSAR (quantitative structure-activity relationship) studies on related compounds.

[1]  J Deisenhofer,et al.  Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.

[2]  D. Lewis.  Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  I. Roots,et al.  Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test , 1994, Clinical pharmacology and therapeutics.

[4]  J. Domergue,et al.  Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. , 1994, The Journal of pharmacology and experimental therapeutics.

[5]  M H Tarbit,et al.  Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  T. Andersson.  Omeprazole Drug Interaction Studies , 1991, Clinical pharmacokinetics.

[7]  G. Lucier,et al.  Omeprazole, cytochrome P450, and chemical carcinogenesis. , 1992, Gastroenterology.

[8]  J. Houston,et al.  Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. , 1996, British journal of clinical pharmacology.

[9]  D. Phillips,et al.  Interaction of omeprazole with DNA in rat tissues. , 1992, Mutagenesis.

[10]  T. Matsushima,et al.  Genotoxicity and cell proliferative activity of omeprazole in rat stomach mucosa. , 1991, Mutation research.

[11]  G. Farrell,et al.  Human cytochrome P450 isoforms , 1990 .

[12]  K. Ruckpaul,et al.  Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  T. Humphries.  Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole , 1991, Digestive diseases and sciences.

[14]  D. Lewis,et al.  Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). , 1997, Drug metabolism reviews.

[15]  G. Wilkinson,et al.  In vivo and in vitro measurement of CYP2C19 activity. , 1996, Methods in enzymology.

[16]  F. Gonzalez,et al.  Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. , 1994, Drug metabolism reviews.

[17]  C. Funck-Brentano,et al.  Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. , 1997, The Journal of pharmacology and experimental therapeutics.

[18]  A. Parkinson,et al.  Omeprazole and the induction of human cytochrome P-450: a response to concerns about potential adverse effects. , 1991, Gastroenterology.

[19]  R. Chenery,et al.  The interaction of omeprazole with rat liver cytochrome P450-mediated monooxygenase reactions in vitro and in vivo. , 1988, Biochemical pharmacology.

[20]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[21]  P. Maurel,et al.  Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor. , 1992, Biochemical and biophysical research communications.

[22]  D. Lewis,et al.  Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  J Ashby,et al.  Consideration of CASE predictions of genotoxic carcinogenesis for omeprazole, methapyrilene and azathioprine. , 1992, Mutation research.

[24]  F. Guengerich.  Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. , 1988, Cancer research.

[25]  A. Beresford,et al.  CYP1A1: friend or foe? , 1993, Drug metabolism reviews.

[26]  R. Gugler,et al.  Inhibition of human liver cytochrome P-450 by omeprazole. , 1986, British journal of clinical pharmacology.

[27]  G. Sachs,et al.  The pharmacology of the gastric acid pump: the H+,K+ ATPase. , 1995, Annual review of pharmacology and toxicology.

[28]  J. Miners,et al.  Assays of omeprazole metabolism as a substrate probe for human CYP isoforms. , 1996, Methods in enzymology.

[29]  A. J. Ryan,et al.  The binding to oxidised cytochromes P-450 and inhibition of mixed-function oxidases by aryl-substituted benzimidazoles and related compounds. , 1983, Chemico-biological interactions.

[30]  B Honig,et al.  Reconciling the magnitude of the microscopic and macroscopic hydrophobic effects. , 1991, Science.

[31]  J. Brockmöller,et al.  Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C‐[N‐3‐methyl]‐caffeine breath test in poor and extensive metabolizers of S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[32]  T. Shimada,et al.  Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. , 1989, Cancer research.

[33]  D. Lewis,et al.  The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: potential importance to its proposed anti-carcinogenic/carcinogenic actions. , 1996, Carcinogenesis.

[34]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.

[35]  M H Tarbit,et al.  Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[36]  I. Roots,et al.  Specific and dose‐dependent enzyme induction by omeprazole in human beings , 1994, Hepatology.

[37]  A. Martelli,et al.  Lack of evidence of omeprazole genotoxicity in Sprague-Dawley rats. , 1993, Mutagenesis.

[38]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[39]  T. Richardson,et al.  Alterations of the regiospecificity of progesterone metabolism by the mutagenesis of two key amino acid residues in rabbit cytochrome P450 2C3v. , 1994, The Journal of biological chemistry.

[40]  S. Binkley,et al.  Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. , 1996, Pharmacogenetics.

[41]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.

[42]  D. Flockhart,et al.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[43]  J. Houston,et al.  Selectivity of omeprazole inhibition towards rat liver cytochromes P450. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[44]  G. Farrell.  P450IA2 and omeprazole. , 1992, Gastroenterology.

[45]  L Ekman,et al.  Toxicological studies on omeprazole. , 1985, Scandinavian journal of gastroenterology. Supplement.

[46]  L. Pedersen,et al.  Identification of Residues 99, 220, and 221 of Human Cytochrome P450 2C19 as Key Determinants of Omeprazole Hydroxylase Activity (*) , 1996, The Journal of Biological Chemistry.

[47]  M H Tarbit,et al.  Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[48]  C. Ioannides,et al.  Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. , 1993, Drug metabolism reviews.

[49]  A. Doig,et al.  Toward the semiquantitative estimation of binding constants guides for peptide peptide binding in aqueous solution , 1991 .

[50]  Raimund Mannhold,et al.  On the Reliability of Calculated Log P-values: Rekker, Hansch/Leo and Suzuki Approach , 1993 .

[51]  B. Kemper,et al.  A single amino acid substitution confers progesterone 6 beta-hydroxylase activity to rabbit cytochrome P450 2C3. , 1993, The Journal of biological chemistry.

[52]  J. Goldstein,et al.  Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[53]  D. Lewis,et al.  Cytochromes P450: structure, function and mechanism. , 1996 .

[54]  P. Maurel,et al.  Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. , 1990, Gastroenterology.